Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 3/20 | 0.47 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23353907 | 0.85 | RAB9A (0.43) | MEN1KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL15142870 | 0.84 | NPFFR1 (0.51) | NPFFR1NPFFR2MEN1KMT2AMAPT | |
| SCHEMBL30897414 | 0.84 | GAA (0.44) | NPFFR1NPFFR2MAPTTDP1GAA | |
| SCHEMBL4882935 | 0.84 | NPFFR1 (0.41) | NPFFR1NPFFR2MEN1KMT2AMAPT | |
| SCHEMBL29598182 | 0.83 | NOS3 (0.45) | NPFFR1NPFFR2MAPTMAPK1TDP1 | |
| SCHEMBL17560548 | 0.82 | NOS1 (0.47) | NPFFR1NPFFR2MEN1KMT2AMAPT | |
| SCHEMBL3798328 | 0.81 | MIF (0.43) | NPFFR1NPFFR2MEN1KMT2AMAPT | |
| SCHEMBL3804463 | 0.81 | NPFFR1 (0.46) | NPFFR1NPFFR2RAB9ANPC1GAA | |
| SCHEMBL18782090 | 0.81 | CA12 (0.42) | NPFFR1NPFFR2MEN1KMT2AMAPT | |
| SCHEMBL17560318 | 0.81 | HTR3E (0.50) | NPFFR1NPFFR2MAPTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110156641-B | Synthesis method of substituted guanidine | 西安近代化学研究所 | 2022-06-10 | — | — | CN | disclosed |
| US-20030055214-A1 | Guanidinylation reagents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-03-20 | — | — | US | disclosed |
| EP-0983232-B1 | GUANIDINYLATION REAGENTS | UNIV CALIFORNIA (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6380358-B1 | USING IN SOLID PHASE SYNTHESIS; FOR EXAMPLE, N-N'-DI-BOC-N?-TRIFLUOROMETHMESULFONYL-GUANIDINE TO YIELD N-PROTECTED GUANIDINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-30 | — | — | US | disclosed |
| US-6072075-A | Guanidinylation reagents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0983232-A2 | GUANIDINYLATION REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052917-A2 | GUANIDINYLATION REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055214-A1 | Guanidinylation reagents | GDA, GMPS, GNMT | NPFFR1 2372/4885NPFFR2 1675/4885MEN1 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.